Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study

Table 1 Selected demographic and clinical characteristics of breast cancer patients included in the Shanghai Breast Cancer Survival Study.

Variables	Levels	Number of cases	%	5-year survival rate	P
Age at diagnosis	<40	126	4.51	0.9029	<0.01
	40-49	1128	40.42	0.9166
	50-59	794	28.45	0.8827
	60-69	469	16.8	0.8586
	≥70	274	9.82	0.8356
Education	<Middle School	361	12.93	0.7941	<0.01
	Middle School	988	35.40	0.8948
	> Middle School	1442	51.67	0.9096
Income	<1,000	1723	61.73	0.8696	<0.01
(CNY¥/person/month)	1,000 - 1,999	777	27.84	0.9141
	≥2,000	291	10.43	0.9415
TNM stage	0	63	2.26	1.0000	<0.01
	I	871	31.21	0.9545
	IIa	945	33.86	0.9221
	IIb	549	19.67	0.8174
	III-IV	272	9.75	0.6724
Histologic grade	I	438	15.69	0.9611	<0.01
	II	1312	47.01	0.9002
	III	803	28.77	0.8274
	Unknown	238	8.53	0.9231
Histologic type*	Noninvasive (DCIS, LCIS)	96	3.44	1.0000	<0.01
	ILC NOS	215	7.70	0.8797
	IDC NOS	1924	68.94	0.8745
	Special types	527	18.88	0.9264
	Unknown	29	1.04	0.8966
ERα	Positive (> = 10%)	1740	62.34	0.9206	<0.01
	Negative	1051	37.66	0.8354
PR	Positive (> = 1%)	1632	58.47	0.9183	<0.01
	Negative	1159	41.53	0.8465
HER2	Positive (3+)	849	30.42	0.8621	0.02
	Borderline (2+)	227	8.13	0.8768
	Negative (0-1+)	1715	61.45	0.9032
Molecular subtype**	Luminal A	1355	48.55	0.9286	<0.01
	Luminal B	467	16.73	0.8862
	HER2	382	13.69	0.8322
	Triple negative	360	12.90	0.8069
	HER2 borderline	227	8.13	0.8768
Radiotherapy	Yes	874	31.31	0.8409	<0.01
	No	1917	68.69	0.9098
Chemotherapy	Yes	2558	91.65	0.8890	0.99
	No	233	8.35	0.8818
Immunotherapy	Yes	477	17.09	0.9118	0.18
	No	2310	82.77	0.8844
	Unknown	4	0.14	0.7500
Tamoxifen ***	Yes	1484	53.17	0.9123	<0.01
	No	1306	46.79	0.8612

*DCIS: ductal carcinoma in situ; LCIS: lobular carcinoma in situ; IDC NOS: invasive ductal carcinoma not otherwise specified; ILC NOS: invasive lobular carcinoma not otherwise specified; Special types: including mucinous, papillary, medullary, tubular, cribriform, metaplastic, mixed, and other rare invasive cancers.
** Luminal A: ERα+ and/or PR+, HER2-; luminal B: ERα+ and/or PR+, HER2+; HER2: HER2+, ERα-, and PR-; triple negative: ERα-, PR-, HER2-: HER2 borderline: weak staining of HER2 (2+).
***One case with unknown tamoxifen use was excluded.

ISSN: 1471-2407